• Lantern Pharma released updated Phase 2 HARMONIC trial results, already being used for partnering and clinical discussions during ASCO 2026.
• Data reinforced a pattern of longer treatment translating into better disease control in EGFR L858R-mutant lung cancer following prior targeted therapy.
• Responses appeared durable in some patients, with tumor shrinkage seen in a majority of those evaluable in the L858R subgroup.
• A protocol change cleared by the FDA extends LP-300 dosing to eight cycles, reflecting confidence in sustained tolerability.
• Safety remained consistent with standard chemotherapy, supporting longer use in a heavily pretreated population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606020813BIZWIRE_USPR_____20260602_BW549826) on June 02, 2026, and is solely responsible for the information contained therein.